Arca
Skip to content

Warning Letter to Abraxis Bioscience LLC

Drugs. See Abraxis BioScience's company page or this site's inspections.

On Jan 18, 2024, FDA's CDER sent Abraxis Bioscience LLC a warning letter.

  • Letter date: Jan 18, 2024
  • Issued by: CDER
  • Closeout: —

The Letter

As posted on FDA.gov ↗; cited 21 CFR sections link to their page.

Dear Mr. Trembath:

The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter # 633713 dated October 31, 2022.

Based on our evaluation, it appears that you have addressed the violation contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority.

The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely, /S/ Joan Johnson Compliance Officer Division of Drug Quality I

The Firm's Other Letters

Same company or the same FDA site, newest first

Record

Recipient
Nathan Trembath
FDA site ID (FEI)
3006441852
Cited
—

Tags are assigned by Arca from the letter's text. A closeout letter means FDA found the firm's corrections adequate; no closeout does not mean the issues are unresolved. FDA warning letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.